Stocks / NYSE / Myovant Sciences Ltd.

Myovant Sciences Ltd.

Our Opinion

Myovant Sciences Ltd. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.

Supporting Evidence:

The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.

“The overall safety profile to date and the observed effects on the pituitary-gonadal axis in animals and humans support the continued development of RVT-602.” (Page 102) Read the full document

Company Description

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It specializes in development and commercialization of innovative therapies for women’s health diseases and other endocrine-related disorders. It focuses on product candidate, relugolix, for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer, as well as in RVT-602, for the treatment of female infertility as part of assisted reproduction. The company was founded on February 2, 2016 and is headquartered in Hamilton, Bermuda. [Source: MarketWatch]

Company Website: